BBB Foods Inc. (NYSE:TBBB) filed a Form 6-K on November 2, 2026, reporting its consolidated financial results for the third quarter ended September 30, 2026.
Reitar Logtech Holdings Limited filed a Form 6-K on November 2, 2026, reporting the results of an extraordinary general meeting held the same day at which shareholders approved a 10-for-1 share consolidation for both Class A and Class B ordinary shares.
Morgan Stanley Finance LLC filed a free writing prospectus on November 2, 2026, disclosing preliminary terms for Contingent Income Memory Auto-Callable Securities due November 28, 2031, linked to the S&P 500 Futures 40% Intraday 4% Decrement VT Index (SPXF40D4), with CUSIP 61781TSB0.
PomDoctor Limited filed a Form 6-K with the SEC on November 2, 2026, disclosing receipt of two Nasdaq deficiency letters on October 28, 2026, related to failures to meet minimum market value of listed securities and market value of publicly held shares requirements.
Morgan Stanley Finance LLC filed a Free Writing Prospectus to Preliminary Pricing Supplement No. 19,688 on November 2, 2026, outlining terms for SX5E Dual Directional Buffered PLUS securities due November 28, 2031.
Morgan Stanley Finance LLC filed a Free Writing Prospectus on November 2, 2026, for Step-Up Jump Notes with an Auto-Callable Feature linked to the Morgan Stanley Amplitude Index (MSAMP5), with a scheduled maturity of November 30, 2033.
Antelope Enterprise Holdings Ltd. filed a Form 6-K on November 2, 2026, disclosing the September 10, 2026 entry into a Note Purchase Agreement with an accredited investor for the issuance and sale of a $6,000,000 convertible promissory note in a registered direct offering.
Morgan Stanley Finance LLC filed a Free Writing Prospectus on November 2, 2026, disclosing preliminary terms for Contingent Income Auto-Callable Securities linked to the S&P 500 Futures 40% Intraday 4% Decrement VT Index, with a maturity date of November 28, 2031.
CollPlant Biotechnologies Ltd. filed a Form 6-K on November 2, 2026, disclosing that its Board of Directors replaced Yehiel Tal as Chief Executive Officer with Eran Rotem, effective immediately, as part of a broader cost-reduction plan that includes discontinuing regenerative medicine research and development …
Morgan Stanley Finance LLC filed a Free Writing Prospectus to Preliminary Pricing Supplement No. 19,856 on November 2, 2026, disclosing terms for its MSAMP5 Market-Linked Notes due August 29, 2028, linked to the Morgan Stanley Amplitude Index.